First-Line TKIs Less Effective in Non-Clear-Cell Renal Cell Carcinoma

According to a study that was published in Urologic Oncology, patients with metastatic non-clear-cell renal cell carcinoma (nccRCC) have worse outcomes from first-line therapy with tyrosine kinase inhibitors (TKIs) than patients with metastatic clear-cell RCC (ccRCC).01/31/2019
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news